Destructive procedures are the standard of care for treatment of actinic keratoses

被引:53
作者
Feldman, SR [1 ]
Fleischer, AB [1 ]
Williford, PM [1 ]
Jorizzo, JL [1 ]
机构
[1] Wake Forest Univ, Sch Med, Westwood Squibb Ctr Dermatol Res, Dept Dermatol, Winston Salem, NC 27157 USA
关键词
D O I
10.1016/S0190-9622(99)70526-8
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Actinic keratoses are premalignant lesions resulting from exposure to carcinogens. Recently, some Medicare carriers have limited reimbursement for destruction of actinic keratoses to those lesions unresponsive to topical 5-fluorouracil treatment. Objective: Our purpose was to determine whether this policy meets the community standard of care for treatment of actinic keratoses. Methods: Data from the 1993 and 1994 National Ambulatory Medical Care Survey were used to determine the frequencies at which different treatments are used for actinic keratoses. These were compared with the frequencies at which procedures and medical therapies are used to treat control conditions (warts, psoriasis, acne, and dermatitis) to determine whether procedures are done because they are available or out of medical necessity. Results: Procedures were performed during 78% of visits for actinic keratoses. 5-Fluorouracil was used at 3.6% of visits, and at 39% of these visits a procedure was also performed. There were no observations of use of 5-fluorouracil alone at a first visit for actinic keratosis. Procedures were less likely to be performed at visits for warts, psoriasis, acne, or dermatitis, which indicates that reimbursable procedures are performed not simply because they are available. Conclusion: Procedures are, performed to destroy actinic keratoses out of medical need. Medicare policies mandating initial use of 5-fluorouracil as initial treatment of actinic keratoses do not represent the community standard of care for treatment of these lesions.
引用
收藏
页码:43 / 47
页数:5
相关论文
共 27 条
[1]  
*AM AC DERM, 1997, IND CHECKL DOC REQ R
[2]   CYCLIN-D AND RETINOBLASTOMA GENE-PRODUCT EXPRESSION IN ACTINIC KERATOSIS AND CUTANEOUS SQUAMOUS-CELL CARCINOMA IN RELATION TO P53 EXPRESSION [J].
BITO, T ;
UEDA, M ;
AHMED, NU ;
NAGANO, T ;
ICHIHASHI, M .
JOURNAL OF CUTANEOUS PATHOLOGY, 1995, 22 (05) :427-434
[3]   NONINFLAMMATORY DESTRUCTION OF ACTINIC KERATOSES BY FLUOROURACIL [J].
BREZA, T ;
TAYLOR, JR ;
EAGLESTEIN, WH .
ARCHIVES OF DERMATOLOGY, 1976, 112 (09) :1256-1258
[4]   Actinic keratoses [J].
Callen, JP ;
Bickers, DR ;
Moy, RL .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 36 (04) :650-653
[5]  
CEILLEY RI, 1997, PRESIDENTS MESSAGE, P1
[6]   Dermabrasion for prophylaxis and treatment of actinic keratoses [J].
Coleman, WP ;
Yarborough, JM ;
Mandy, SH .
DERMATOLOGIC SURGERY, 1996, 22 (01) :17-21
[7]  
COTRAN RS, 1994, PATHOLOGIC BASIS DIS, P1033
[8]   ACTINIC KERATOSES INDUCED BY A SUNBED [J].
COX, NH .
BRITISH MEDICAL JOURNAL, 1994, 308 (6934) :977-978
[9]   SELECTIVE CYTOTOXIC EFFECT OF TOPICAL 5-FLUOROURACIL [J].
DILLAHA, CJ ;
HONEYCUTT, WM ;
BRADFORD, AC ;
JANSEN, GT .
ARCHIVES OF DERMATOLOGY, 1963, 88 (03) :247-+
[10]  
Dinehart SM, 1997, CANCER, V79, P920, DOI 10.1002/(SICI)1097-0142(19970301)79:5<920::AID-CNCR8>3.0.CO